In this trial, 195 patients with node-positive or high-risk node-negative HER2-expressing (IHC 1+, 2+, 3+) early-stage breast cancer, who completed all standard first-line therapies, received vaccination with nelipepimut-S. Here, ERBB2 is linked to breast cancer.